Protara Therapeutics Q1 EPS $(0.97) Misses $(0.95) Estimate
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics reported Q1 EPS of $(0.97), missing the consensus estimate of $(0.95) by 2.11%. This represents a 21.25% increase in losses compared to $(0.80) per share from the same period last year.
May 02, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Protara Therapeutics reported a larger than expected quarterly loss, missing analyst estimates.
Missing the EPS estimate and reporting increased losses year-over-year is generally seen negatively by the market, likely leading to a short-term negative impact on TARA's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100